Neratinib, another tyrosine kinase inhibitor that targets HER2 (human epidermal growth factor receptor 2) and, to a lesser extent, EGFR (epidermal growth factor receptor), promotes ferroptosis and suppresses brain metastasis in HER2-positive breast cancer when used as neoadjuvant therapy, primarily by increasing intracellular iron levels [192]. Here, ERBB2 is linked to breast cancer.